Literature DB >> 20678071

Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease.

B Kovacech1, M Novak.   

Abstract

Deposits of the misfolded neuronal protein tau are major hallmarks of neurodegeneration in Alzheimer's disease (AD) and other tauopathies. The etiology of the transformation process of the intrinsically disordered soluble protein tau into the insoluble misordered aggregate has attracted much attention. Tau undergoes multiple modifications in AD, most notably hyperphosphorylation and truncation. Hyperphosphorylation is widely regarded as the hottest candidate for the inducer of the neurofibrillary pathology. However, the true nature of the impetus that initiates the whole process in the human brains remains unknown. In AD, several site-specific tau cleavages were identified and became connected to the progression of the disease. In addition, western blot analyses of tau species in AD brains reveal multitudes of various truncated forms. In this review we summarize evidence showing that tau truncation alone is sufficient to induce the complete cascade of neurofibrillary pathology, including hyperphosphorylation and accumulation of misfolded insoluble forms of tau. Therefore, proteolytical abnormalities in the stressed neurons and production of aberrant tau cleavage products deserve closer attention and should be considered as early therapeutic targets for Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20678071     DOI: 10.2174/156720510793611556

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  27 in total

1.  Pathological Alterations of Tau in Alzheimer's Disease and 3xTg-AD Mouse Brains.

Authors:  Longfei Li; Yanli Jiang; Wen Hu; Yunn Chyn Tung; Chunling Dai; Dandan Chu; Cheng-Xin Gong; Khalid Iqbal; Fei Liu
Journal:  Mol Neurobiol       Date:  2019-02-08       Impact factor: 5.590

2.  Truncation of Tau selectively facilitates its pathological activities.

Authors:  Jianlan Gu; Wen Xu; Nana Jin; Longfei Li; Yan Zhou; Dandan Chu; Cheng-Xin Gong; Khalid Iqbal; Fei Liu
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

3.  Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation.

Authors:  Christopher L Moore; Michael H Huang; Shauna A Robbennolt; Kellen R Voss; Benjamin Combs; T Chris Gamblin; Warren J Goux
Journal:  Biochemistry       Date:  2011-11-29       Impact factor: 3.162

Review 4.  Signaling pathways and posttranslational modifications of tau in Alzheimer's disease: the humanization of yeast cells.

Authors:  Jürgen J Heinisch; Roland Brandt
Journal:  Microb Cell       Date:  2016-03-25

5.  Characterization of microtubule-associated protein tau isoforms and Alzheimer's disease-like pathology in normal sheep (Ovis aries): relevance to their potential as a model of Alzheimer's disease.

Authors:  Emma S Davies; Russell M Morphew; David Cutress; A Jennifer Morton; Sebastian McBride
Journal:  Cell Mol Life Sci       Date:  2022-10-21       Impact factor: 9.207

Review 6.  Describing sequence-ensemble relationships for intrinsically disordered proteins.

Authors:  Albert H Mao; Nicholas Lyle; Rohit V Pappu
Journal:  Biochem J       Date:  2013-01-15       Impact factor: 3.857

Review 7.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

Review 8.  Fairy "tails": flexibility and function of intrinsically disordered extensions in the photosynthetic world.

Authors:  Gabriel Thieulin-Pardo; Luisana Avilan; Mila Kojadinovic; Brigitte Gontero
Journal:  Front Mol Biosci       Date:  2015-05-19

Review 9.  Nuclear Tau and Its Potential Role in Alzheimer's Disease.

Authors:  Mahmoud Bukar Maina; Youssra K Al-Hilaly; Louise C Serpell
Journal:  Biomolecules       Date:  2016-01-07

Review 10.  Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.

Authors:  Lidia Bakota; Roland Brandt
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.